NR3C2 and prostate cancer: Smith Smith MR MR Androgen receptor anomalies and efficacy of apalutamide in patients with nonmetastatic castration-resistant prostate cancer from the phase 3 SPARTAN study Androgen receptor anomalies and efficacy of apalutamide in patients with nonmetastatic castration-resistant prostate cancer from the phase 3 SPARTAN study 2018 2018